drugset / Trial / NCT00191191
To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)
RandomizedParallel-groupOpen-labelTreatment
Summary
To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2004-10
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 1000 mg/m2 | Intravenous |